However sales of some of these agentsincluding Mirapex/Mirapexin/Sifrol and Requip XL/LP/RP/Modutab

However, sales of some of these agents,including Mirapex/Mirapexin/Sifrol and Requip XL/LP/RP/Modutab, will be offsetby increased uptake of generic equivalents. As a result, sales of Parkinson's diseasetherapies will increase modestly from $2.5 billion in 2008 to $2.8 billion in2018 in the United States, France, Germany, Italy, Spain, the United Kingdomand Japan.The new Pharmacor report entitled Parkinson's Disease finds that the majorityof market sales will continue to be driven by the dopamine agonist drug classthat includes Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol,GlaxoSmithKline's Requip, GlaxoSmithKline/SkyePharma's Requip XL/LP/RP/Modutaband UCB/Schwarz Pharma's Neupro. Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of SeveralNew Therapies, Will be Offset by Generic Erosion of Key AgentsOverall Market Will Increase by a Modest $300 Million From 2008 to 2018,According to a New Report from Decision ResourcesWALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world'sleading research and advisory firms for pharmaceutical and healthcare issues,finds that growth in the Parkinson's disease drug market, fueled by the launchof several new therapies through 2018, will be offset by generic erosion ofkey currently-available agents. For more information, visit Ryan201-265-6498SOURCEPeminic, Inc.Chris Ryan of Peminic, Inc., +1-201-265-6498.

Founded in 2002, Peminic has thelargest deployment of online Incident Reporting, Patient Relations, andCompliance in the United States. Peminic's healthcareIT workflow and process management platform, powered by Peminic's proprietaryWEBAgent technology, allows tremendous flexibility in configuring itsapplications to meet clients' specific needs. is a leading software provider in the areas of Patient Safety,Patient Relations, Risk Management, and Legal Services. "Matter's process driven and disciplined approach indeveloping a growth and client-focused infrastructure is among the mosteffective in the industry, resulting in high levels of success, clientsatisfaction, and long-lasting, mutually rewarding relationships."About Peminic:Peminic, Inc. LeonardIII, Board Chairman of Peminic and Managing Director of Coady Diemar PartnersInvestment Bank, New York City and former CEO of Solucient, Inc., now part ofThomson Reuters. It speaks to our willingness to invest in the best of breed tosatisfy the needs of our customers and as well of Bruce's recognition of thetremendous growth opportunities available to Peminic," said Charles E. Matterhas a proven track record for providing strategic solutions that focus onimproved outcomes, exceeding client expectations, and patient satisfaction.Matter brings over 25 years of sales, marketing, and client relationsexperience from IBM, Cerner, McKesson, Eclipsys and, most recently,GetWellNetwork, where he departed after several years of leading their growthand market visibility efforts, far exceeding industry standards."Peminic is extremely fortunate to have attracted someone with Bruce Matter'slevel of accomplishment, experience, and leadership in high growthenvironments.

Peminic, with offices in Princeton,Kansas City and Dallas, provides workflow and process management solutions toover 400 acute care and other healthcare providers for patient safety, patientrelations, risk management and legal matters.Teaming with hospitals, health systems, and industry associations, Mr. as Company Growth in the Areas of Patient Safety, RiskManagement, and Patient Satisfaction AcceleratesPRINCETON, N.J., June 9 /PRNewswire/ -- Bruce Matter has joined healthcare ITsoftware provider, Peminic, Inc., as Executive Vice President, responsible forcompany growth and client satisfaction. Industry Recognized and Trusted Leader, Bruce Matter, Joins Healthcare ITCompany, Peminic, Inc. Although we believe that thebeliefs, plans, expectations and intentions contained in this pressrelease are reasonable, there can be no assurance that such beliefs,plans, expectations or intentions will prove to be accurate.ON BEHALF OF THE BOARDGalloway Energy Inc.- - - - - - - - - - - - - - - - - -Shane LowryPresident and Chief Executive OfficerContact:Galloway Energy, Inc.310-933-5883Email Contact 2009, Market Wire, All rights reserved.-0-.

Theseforward-looking statements are made as of the date of this news release,and we assume no obligation to update the forward-looking statements, orto update the reasons why actual results could differ from thoseprojected in the forward-looking statements. Such factors include,among others, the inherent uncertainties associated with petroleumexploration and development stage exploration companies. Actual results could differ from those projected in anyforward-looking statements due to numerous factors. Such forward-lookingstatements include, among other things, the development, costs and resultsof our exploration program at our energy properties and any anticipatedfuture production. Statements in thispress release which are not purely historical are forward-lookingstatements and include any statements regarding beliefs, plans,expectations or intentions regarding the future.